Education
About Us
Working with TipRanks
Follow Us
Abeona Therapeutics (ABEO)
NASDAQ:ABEO
ABEO Stock Chart & Stats
$4.45
-$0.15(-2.50%)
At close: 4:00 PM EST
$4.45
-$0.15(-2.50%)
Day’s Range― - ―
52-Week Range$3.93 - $7.54
Previous CloseN/A
Volume71.38K
Average Volume (3M)1.23M
Market Cap
$253.87M
Enterprise Value$187.68M
Total Cash (Recent Filing)$191.40M
Total Debt (Recent Filing)$24.97M
Price to Earnings (P/E)3.9
Beta0.94
Next Earnings
May 20, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding57,049,023
10 Day Avg. Volume1,855,258
30 Day Avg. Volume1,231,466
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.75
Price to Sales (P/S)47.95
P/FCF Ratio-3.31
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue32.25
Enterprise Value/Gross Profit122.51
Enterprise Value/Ebitda-2.19
Forecast
1Y Price Target
$21.40Price Target Upside380.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.73
Revenue Forecast (FY)$65.61M
Bulls Say, Bears Say
Bulls Say
Commercial RolloutProgressing commercial rollout with initial patients treated and multiple biopsies moving through the manufacturing process establishes institutional workflows that can accelerate patient throughput and streamline referral-to-treatment timelines.
Market Access And ReimbursementMajor commercial insurers and Medicaid programs publishing coverage policies for ZEVASKYN reduces reimbursement barriers and supports broader patient access, improving potential uptake.
Regulatory And Clinical DataRegulatory resubmission for UX111 that includes longer-term clinical and biomarker data and an acknowledged neurodevelopmental outcome set increases the potential for approval and could provide meaningful upside through royalties and milestones.
Bears Say
Manufacturing CapacityCurrent manufacturing capacity that supports only a limited number of patient treatments per month may constrain near-term commercial momentum and delay the expected revenue ramp until production is expanded.
Abeona Therapeutics News
ABEO FAQ
What was Abeona Therapeutics’s price range in the past 12 months?
Abeona Therapeutics lowest stock price was $3.93 and its highest was $7.54 in the past 12 months.
What is Abeona Therapeutics’s market cap?
Abeona Therapeutics’s market cap is $253.87M.
When is Abeona Therapeutics’s upcoming earnings report date?
Abeona Therapeutics’s upcoming earnings report date is May 20, 2026 which is in 58 days.
How were Abeona Therapeutics’s earnings last quarter?
Abeona Therapeutics released its earnings results on Mar 17, 2026. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of -$0.352 by -$0.008.
Is Abeona Therapeutics overvalued?
According to Wall Street analysts Abeona Therapeutics’s price is currently Undervalued.
Does Abeona Therapeutics pay dividends?
Abeona Therapeutics does not currently pay dividends.
What is Abeona Therapeutics’s EPS estimate?
Abeona Therapeutics’s EPS estimate is -0.34.
How many shares outstanding does Abeona Therapeutics have?
Abeona Therapeutics has 57,049,023 shares outstanding.
What happened to Abeona Therapeutics’s price movement after its last earnings report?
Abeona Therapeutics reported an EPS of -$0.36 in its last earnings report, missing expectations of -$0.352. Following the earnings report the stock price went down -3.838%.
Which hedge fund is a major shareholder of Abeona Therapeutics?
Currently, no hedge funds are holding shares in ABEO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abeona Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.40 (380.90% Upside)
$21.40 (380.90% Upside)
Blogger Sentiment
Bullish
ABEO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.42%
12-Months-Change
Fundamentals
Return on Equity
53.18%
Trailing 12-Months
Asset Growth
103.04%
Trailing 12-Months
Company Description
Abeona Therapeutics
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
ABEO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted several strong positives: a transformative one-time gain from the priority review voucher that produced a substantial net income swing and strengthened cash; regulatory and reimbursement progress (J-code and broad payer coverage); growing patient identification (50 to +100); and an on-track manufacturing capacity expansion to ~10 patients/month. However, meaningful operational risks and near-term commercialization challenges remain: an earlier sterility-related batch failure and launch delay, slow initial patient throughput (only two treated to date), a lengthy 4–5 month timeline from consult to treatment, and sharply higher SG&A as the company transitions to commercial operations. While early commercial traction is improving and the company has sufficient liquidity, execution of QTC onboarding and consistent patient cadence are critical to meet profitability and scale expectations.View all ABEO earnings summariesABEO Stock 12 Month Forecast
Average Price Target
$21.40
▲(380.90% Upside)
Technical Analysis
Ownership Overview
7.20% Insiders
7.09% Mutual Funds
45.04% Other Institutional Investors
31.46% Public Companies and
Individual Investors